{"product_id":"ifrx-vrio-analysis","title":"InflaRx N.V. (IFRX): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs InflaRx N.V. (IFRX) truly built for lasting success? This VRIO analysis rigorously tests the core of their business - its Value, Rarity, Inimitability, and Organization - to uncover whether they possess a sustainable competitive advantage. Dive in now to see the definitive verdict on what truly sets InflaRx N.V. (IFRX) apart from the competition and where their future strength lies.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eInflaRx N.V. (IFRX) - VRIO Analysis: 1. Proprietary Complement System Technology Platform\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at the core engine of InflaRx N.V. (IFRX), which is their proprietary technology platform centered on the complement system. This isn't just some abstract science; it’s the foundation for their key assets, like the monoclonal antibody vilobelimab and the oral inhibitor INF904. The platform’s value is clear: it allows for the discovery of highly specific inhibitors targeting a powerful inflammatory pathway.\u003c\/p\u003e\n\n\u003cp\u003eFor instance, vilobelimab already has European Commission approval for COVID-19-induced ARDS and a US Emergency Use Authorization for critical COVID-19 in mechanically ventilated adults. Still, the focus is shifting, especially after the Phase 3 trial for vilobelimab in pyoderma gangrenosum (PG) was stopped in May 2025 due to futility based on an interim analysis of the first 30 patients. This pivot highlights how the organization is managing its platform assets.\u003c\/p\u003e\n\n\u003cp\u003eThe company is now heavily prioritizing INF904, their oral C5aR inhibitor, with topline Phase 2a data for hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU) expected between late September and early November 2025. They see significant potential here, believing CSU and HS each represent addressable markets of $\\text{€1 billion}$ or more for INF904. This focus on a best-in-class oral option is a direct action based on platform capability.\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on their current financial footing supporting this R\u0026amp;D: for the first half of 2025, revenues were just $\\text{€39,000}$ from US vilobelimab sales, resulting in a net loss of $\\text{€23.0 million}$. Thankfully, they bolstered their position, raising approximately $\\text{\\$30.0 million}$ in gross proceeds from a public offering in February 2025, leaving them with about $\\text{€53.7 million}$ in total funds as of June 30, 2025, which they estimate covers operations into 2027. If onboarding INF904 development takes longer than expected, cash runway management becomes critical.\u003c\/p\u003e\n\n\u003cp\u003eThe platform’s rarity stems from the deep, focused expertise in C5a\/C5aR inhibition, which is tough for smaller biopharma firms to replicate. Imitability is high because developing this level of selective, proprietary molecule discovery requires years of specialized research and, frankly, many failed attempts. The organization appears strong, clearly structured around driving development across these pipeline indications.\u003c\/p\u003e\n\n\u003cp\u003eThe competitive advantage hinges on validation. This foundational science is their moat, assuming the pipeline validates it with successful data readouts for INF904. That’s the near-term action item: watch those INF904 data releases.\u003c\/p\u003e\n\n\u003cp\u003eHere is a summary of the VRIO assessment for the platform:\u003c\/p\u003e\n\n\u003ctable border=\"1\"\u003e\n    \u003ctr\u003e\n        \u003cth\u003eVRIO Dimension\u003c\/th\u003e\n        \u003cth\u003eAssessment\u003c\/th\u003e\n        \u003cth\u003eSupporting 2025 Data\/Context\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003eHigh\u003c\/td\u003e\n        \u003ctd\u003eUnderpins vilobelimab (EU approved\/US EUA) and INF904 pipeline.\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003eRare\u003c\/td\u003e\n        \u003ctd\u003eDeep, focused expertise in C5a\/C5aR inhibition is uncommon.\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003eCostly\/Difficult\u003c\/td\u003e\n        \u003ctd\u003eRequires years of specialized research and failed attempts to replicate.\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003eStrong\u003c\/td\u003e\n        \u003ctd\u003eCompany is organized around the platform, pivoting resources to INF904 after PG trial futility in May 2025.\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003eSustained (Conditional)\u003c\/td\u003e\n        \u003ctd\u003eMoat depends on successful validation of pipeline candidates like INF904 (Phase 2a data expected Nov 2025 for $\\text{€1 billion+}$ markets).\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe key takeaways for you right now are:\u003c\/p\u003e\n\u003cul\u003e\n    \u003cli\u003eVilobelimab revenue for H1 2025 was only $\\text{€39,000}$.\u003c\/li\u003e\n    \u003cli\u003eINF904 targets CSU\/HS, each a potential $\\text{€1 billion+}$ market.\u003c\/li\u003e\n    \u003cli\u003eThe PG Phase 3 trial was stopped for futility in May 2025.\u003c\/li\u003e\n    \u003cli\u003eCash runway extends into 2027 based on $\\text{€53.7 million}$ on June 30, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFinance: draft the sensitivity analysis for a 6-month delay in INF904 Phase 2a data by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eInflaRx N.V. (IFRX) - VRIO Analysis: 2. INF904 Oral C5aR Inhibitor Asset\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eINF904 offers a potential best-in-class, orally administered option for Chronic Spontaneous Urticaria (CSU) and Hidradenitis Suppurativa (HS). InflaRx believes CSU and HS each has a potential addressable market of \u003cstrong\u003e$1 billion or more\u003c\/strong\u003e for INF904. The HS market is projected to reach \u003cstrong\u003e$15 billion by 2035\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eModerate; oral small molecules targeting C5aR are sought after, but INF904’s specific profile might be unique.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTemporary; competitors will try to develop similar oral agents, but the lead position is valuable.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGood; the company is prioritizing resources toward INF904 development following the Pyoderma Gangrenosum (PG) trial stoppage. The company reported cash, cash equivalents, and marketable securities of \u003cstrong\u003e€55.2 million\u003c\/strong\u003e as of \u003cstrong\u003eDecember 31, 2024\u003c\/strong\u003e, subsequently increased by gross proceeds of \u003cstrong\u003e€28.7 million\u003c\/strong\u003e in \u003cstrong\u003eFebruary 2025\u003c\/strong\u003e. Total funds available were \u003cstrong\u003e€53.7 million\u003c\/strong\u003e on \u003cstrong\u003eJune 30, 2025\u003c\/strong\u003e. The net loss for the six months ended \u003cstrong\u003eJune 30, 2025\u003c\/strong\u003e, was \u003cstrong\u003e€23.0 million\u003c\/strong\u003e. Research and development expenses for the six months ended \u003cstrong\u003eJune 30, 2025\u003c\/strong\u003e, were \u003cstrong\u003e€14.2 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThe Phase 2a basket study for INF904 in CSU and HS includes the following parameters:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTotal patients enrolled: \u003cstrong\u003e75\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCSU patient count: \u003cstrong\u003e45\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eHS patient count: \u003cstrong\u003e30\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTreatment duration evaluated: \u003cstrong\u003e4 weeks\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePhase 3 PG trial interim analysis was expected by the end of \u003cstrong\u003eMay 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTemporary; this advantage hinges entirely on the positive Phase 2a data expected in late \u003cstrong\u003e2025\u003c\/strong\u003e. Topline data from the Phase 2a trial were announced on \u003cstrong\u003eNovember 10, 2025\u003c\/strong\u003e, with the goal of informing Phase 2b study planning by \u003cstrong\u003eyear-end 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eKey INF904 Development and Financial Metrics:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\/Amount\u003c\/td\u003e\n\u003ctd\u003eDate\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated Market Potential (per indication)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1 billion or more\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCSU and HS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHS Market Projection\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$15 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBy 2035\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 2a Total Patients\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e75\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCSU and HS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents \u0026amp; Marketable Securities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€55.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of December 31, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdditional Gross Proceeds Raised\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e€28.7 million\u003c\/strong\u003e (or \u003cstrong\u003e$30.0 million\u003c\/strong\u003e)\u003c\/td\u003e\n\u003ctd\u003eFebruary 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Funds Available\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€53.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of June 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss (H1 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€23.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSix months ended June 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses (H1 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€14.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSix months ended June 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eInflaRx N.V. (IFRX) - VRIO Analysis: 3. Vilobelimab (GOHIBIC) Regulatory Status and Limited Sales\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides a foundation of regulatory precedent, including European Commission approval for ARDS, and generates minimal, but existing, revenue.\u003c\/p\u003e\n\u003cp\u003eVilobelimab (GOHIBIC) received marketing authorization from the European Commission (EC) in January 2025 under exceptional circumstances for the treatment of adult patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS) who are receiving systemic corticosteroids and invasive mechanical ventilation (IMV) with or without extracorporeal membrane oxygenation (ECMO). In the US, it holds Emergency Use Authorization (EUA) for COVID-19 treatment in hospitalized adults receiving IMV or ECMO within 48 hours of initiation.\u003c\/p\u003e\n\u003cp\u003eThe financial contribution from sales remains minimal:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003ePeriod\u003c\/td\u003e\n\u003ctd\u003eSource\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenues from GOHIBIC Sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€39 thousand\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSix months ended June 30, 2025\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChange in GOHIBIC Revenue (YoY)\u003c\/td\u003e\n\u003ctd\u003eDecrease of \u003cstrong\u003e€3 thousand\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eSix months ended June 30, 2025 vs. 2024\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue Attribution\u003c\/td\u003e\n\u003ctd\u003eAll attributed to sales in the United States\u003c\/td\u003e\n\u003ctd\u003eSix months ended June 30, 2025\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOther Income (Non-Revenue)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€1.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSix months ended June 30, 2025\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; having an approved product, even with limited sales, is rare for a company at this stage.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eGOHIBIC is the \u003cstrong\u003efirst and only\u003c\/strong\u003e treatment approved in the EU for SARS-CoV-2-induced ARDS.\u003c\/li\u003e\n\u003cli\u003eThe status of EUA in the US for a specific COVID-19 indication also contributes to its relative rarity among the company's assets.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; competitors can seek similar approvals, but the initial EU approval is a sunk cost advantage.\u003c\/p\u003e\n\u003cp\u003eThe initial achievement of EC marketing authorization under exceptional circumstances represents a sunk cost and first-mover status in the specific EU ARDS indication, creating a barrier to immediate imitation for that specific regulatory pathway.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Mixed; while approved, the PG Phase 3 trial was stopped for futility, showing limits in execution or target validation.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe Independent Data Monitoring Committee (IDMC) recommended stopping the Phase 3 trial for vilobelimab in Pyoderma Gangrenosum (PG) due to \u003cstrong\u003efutility\u003c\/strong\u003e on May 28, 2025.\u003c\/li\u003e\n\u003cli\u003eThe futility decision was based on an interim analysis of the first \u003cstrong\u003e30 patients\u003c\/strong\u003e enrolled in the PG study.\u003c\/li\u003e\n\u003cli\u003eInflaRx announced the intention to \u003cstrong\u003ediscontinue further development\u003c\/strong\u003e of vilobelimab in the PG indication.\u003c\/li\u003e\n\u003cli\u003eThe company projects a cash runway into \u003cstrong\u003e2027\u003c\/strong\u003e, indicating some level of financial planning despite the trial setback.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; the \u003cstrong\u003e€39 thousand\u003c\/strong\u003e in revenue for the first six months of 2025 is negligible, but the EU approval is a plus.\u003c\/p\u003e\n\u003cp\u003eThe primary advantage is the existing regulatory approval in the EU for ARDS, which InflaRx is pursuing commercial partnering for. However, the failure to progress in the PG indication, where analysts had predicted 2030 sales of \u003cstrong\u003e$226 million\u003c\/strong\u003e if successful, significantly tempers the current competitive advantage derived from this asset.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eInflaRx N.V. (IFRX) - VRIO Analysis: 4. Financial Runway and Balance Sheet Strength\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: The €53.7 million in cash and securities as of June 30, 2025, provides a clear runway into 2027 for planned operations.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: Moderate; a 2027 runway is solid for a clinical-stage company, especially after the February 2025 capital raise of €28.7 million in gross proceeds.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: Low; this is a function of past financing decisions, not an inherent operational skill.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: Excellent; disciplined financial management is cited, allowing them to weather pipeline volatility.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Sustained; this financial cushion buys them time to navigate upcoming data readouts without immediate dilution pressure.\u003c\/p\u003e\n\u003cp\u003eKey financial metrics supporting the runway assessment:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash, cash equivalents and marketable securities totaled €53.7 million on June 30, 2025.\u003c\/li\u003e\n\u003cli\u003eNet cash used in operating activities for the six months ended June 30, 2025, was €21.6 million.\u003c\/li\u003e\n\u003cli\u003eThe February 2025 underwritten public offering generated gross proceeds of €28.7 million ($30.0 million).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Metric\u003c\/td\u003e\n\u003ctd\u003eAmount as of June 30, 2025\u003c\/td\u003e\n\u003ctd\u003eAmount as of December 31, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€13.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€18.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarketable Securities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€40.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€36.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Funds Available\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€53.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eApproximately €55.2 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eInflaRx N.V. (IFRX) - VRIO Analysis: 5. Near-Term Clinical Data Catalysts\n\u003c\/h2\u003e\n\u003cp\u003eThe primary value driver for IFRX is the clinical data readout for INF904 in Chronic Spontaneous Urticaria (CSU) and Hidradenitis Suppurativa (HS), with topline results announced on \u003cstrong\u003eNovember 10, 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eThe upcoming topline data for INF904 in CSU and HS (which occurred late September to early November 2025) is the primary value driver for the stock. Positive efficacy signals were observed, including a mean absolute UAS7 reduction of \u003cstrong\u003e16.7 points\u003c\/strong\u003e in the \u003cstrong\u003e60mg\u003c\/strong\u003e CSU cohort after the \u003cstrong\u003e4-week\u003c\/strong\u003e off-drug observational follow-up period.\u003c\/p\u003e\n\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eLow; all clinical-stage companies face data catalysts; this is the nature of the business.\u003c\/p\u003e\n\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eNot applicable; this is a time-bound event, not a resource.\u003c\/p\u003e\n\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eGood; they have a clear schedule for communicating these critical results, including a webcast held on \u003cstrong\u003eNovember 10\u003c\/strong\u003e at \u003cstrong\u003e8:00 AM EST \/ 2:00 PM CET\u003c\/strong\u003e. As of June 30, 2025, cash, cash equivalents and marketable securities totaled \u003cstrong\u003e€53.7 million\u003c\/strong\u003e, with an estimated runway into \u003cstrong\u003e2027\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eNone; this is a binary event, not a sustained advantage.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\/Detail\u003c\/th\u003e\n\u003cth\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eINF904 Phase 2a Trial Duration (Dosing)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4 weeks\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTreatment period for efficacy evaluation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eINF904 Phase 2a Follow-up Duration\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4 weeks\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eObservational follow-up period off-drug\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHS Patients with Efficacy Data Reported\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e29 of 31\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePatients completing 4 weeks of treatment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCSU Patients with Efficacy Data Reported\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e30 of 31\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePatients completing 4 weeks of treatment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCSU UAS7 Mean Absolute Reduction (60mg Cohort)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e16.7 points\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eObserved after 4-week off-drug follow-up\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Equivalents \u0026amp; Securities (June 30, 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€53.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFinancial position to fund operations\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated Cash Runway\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eInto 2027\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBased on currently planned operations\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Cash Used in Operating Activities (6M 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€21.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFor the six months ended June 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eInflaRx N.V. (IFRX) - VRIO Analysis: 6. Strategic Partnership in AAV (Staidson BioPharmaceuticals)\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Validation from a partner (Staidson) using an InflaRx-partnered C5a antibody (BDB-001) showing favorable Phase 1\/2 data in ANCA-associated vasculitis (AAV), potentially leading to a Phase 3 study. The Phase 1\/2 study met its primary efficacy endpoint demonstrating anti-C5a therapy can reduce corticosteroid use and enable corticosteroid-free treatment in AAV patients.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; having a partner advance a molecule based on your core science is a strong external validation signal. The successful Phase 1\/2 data in AAV serves as this signal.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; the specific terms and success of this partnership are unique to InflaRx. The underlying technology is derived from InflaRx's vilobelimab cell line.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Good; it shows the platform's applicability beyond their internal focus areas (e.g., vilobelimab for ARDS\/PG, INF904 for CSU\/HS).\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; the value is realized if Staidson successfully navigates Phase 3. The potential market size for related indications (CSU\/HS) is estimated at over $1 billion each for INF904, suggesting high potential value for the platform.\u003c\/p\u003e\n\n\u003cp\u003eThe financial structure of the collaboration includes distinct royalty streams:\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eAgreement Aspect\u003c\/th\u003e\n\u003cth\u003eChina COVID-19 Indication (BDB-001)\u003c\/th\u003e\n\u003cth\u003eAAV Indication (BDB-001)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalty Rate on Net Sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e10%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eMid-single-digit percentage\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevelopment Status (as of July 2025)\u003c\/td\u003e\n\u003ctd\u003eRegulatory filing planned with NMPA\u003c\/td\u003e\n\u003ctd\u003ePhase 1\/2 met endpoints; Phase 3 planned\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnderlying Technology\u003c\/td\u003e\n\u003ctd\u003eVilobelimab cell line license\u003c\/td\u003e\n\u003ctd\u003eVilobelimab cell line license\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eSupporting financial context for InflaRx as of June 30, 2025:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash, cash equivalents, and marketable securities totaled \u003cstrong\u003e€53.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eEstimated sufficient funds for currently planned operations into \u003cstrong\u003e2027\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet loss for the six months ended June 30, 2025, was \u003cstrong\u003e€23.0 million\u003c\/strong\u003e, or \u003cstrong\u003e€0.35\u003c\/strong\u003e per ordinary share.\u003c\/li\u003e\n\u003cli\u003eRevenue from US vilobelimab sales for the six months ended June 30, 2025, was \u003cstrong\u003e€39,000\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eResearch and development expenses for H1 2025 were \u003cstrong\u003e€14.2 million\u003c\/strong\u003e, a decrease from \u003cstrong\u003e€17.3 million\u003c\/strong\u003e in H1 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eInflaRx N.V. (IFRX) - VRIO Analysis: 7. BARDA-Funded ARDS Clinical Trial\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: Funding from the Biomedical Advanced Research and Development Authority (BARDA) offsets direct R\u0026amp;D cash burn for the vilobelimab ARDS program. Other income for the six months ended June 30, 2025, amounted to \u003cstrong\u003e€1.5 million\u003c\/strong\u003e, primarily due to other income from research allowances.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: Non-dilutive government funding for a critical care platform trial is a resource of moderate rarity. Vilobelimab is one of \u003cstrong\u003ethree\u003c\/strong\u003e host-directed investigational drugs selected for evaluation in the platform study.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: Securing specific federal grants is highly competitive. The specific funding is associated with grant number \u003cstrong\u003e75A50124C00001\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: Leveraging external funding demonstrates effective grant management. The company reported total funds available of \u003cstrong\u003e€53.7 million\u003c\/strong\u003e as of June 30, 2025, with an estimated cash runway into \u003cstrong\u003e2027\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: The advantage is temporary, lasting for the duration of the active funding agreement and trial execution. The estimated Study Completion date is \u003cstrong\u003eJul 01, 2028\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThe JUST BREATHE Phase 2 platform trial details are summarized below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eParameter\u003c\/th\u003e\n\u003cth\u003eDetail\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSponsor\/Funder\u003c\/td\u003e\n\u003ctd\u003eInflaRx \/ \u003cstrong\u003eBARDA\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial Status (as of June 2025)\u003c\/td\u003e\n\u003ctd\u003eEnrollment Began\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget Enrollment\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e600\u003c\/strong\u003e hospitalized adults with ARDS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. Sites\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e60\u003c\/strong\u003e sites\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStudy Design\u003c\/td\u003e\n\u003ctd\u003ePhase 2 multicenter, randomized, double-blind, placebo-controlled\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated Completion\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eJul 01, 2028\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eKey aspects of the resource utilization and funding are:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe trial is a platform design evaluating multiple therapeutic candidates.\u003c\/li\u003e\n\u003cli\u003eVilobelimab is supplied by InflaRx from its available stock.\u003c\/li\u003e\n\u003cli\u003eResearch and development expenses for the six months ended June 30, 2025, decreased by \u003cstrong\u003e€3.1 million\u003c\/strong\u003e to \u003cstrong\u003e€14.2 million\u003c\/strong\u003e compared to the prior year period.\u003c\/li\u003e\n\u003cli\u003eThe trial is managed by PPD Development, LP, contracted by BARDA.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eInflaRx N.V. (IFRX) - VRIO Analysis: 8. Deep Scientific Expertise in Complement Biology\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The company was founded on and continues to pioneer science in the complement cascade, which is essential for developing next-generation inhibitors.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High; this specialized, deep scientific knowledge is difficult to replicate quickly.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High; it is embedded in the team and institutional knowledge, not easily copied.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Strong; the CEO is also the founder, suggesting a strong scientific vision guiding operations.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; this is the core intellectual capital that drives future pipeline creation.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003cth\u003eContext\/Year\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFounding Year\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2007\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCompany Inception\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCEO\/Founder Complement Immunology Experience\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e20 years\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eNiels Riedemann\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead Drug Candidate Milestone\u003c\/td\u003e\n\u003ctd\u003ePhase III completion\u003c\/td\u003e\n\u003ctd\u003eVilobelimab for Hidradenitis Suppurativa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline Candidate Data Release\u003c\/td\u003e\n\u003ctd\u003ePhase 2a Data\u003c\/td\u003e\n\u003ctd\u003eINF904 in Hidradenitis Suppurativa and CSU (Reported November 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Employees\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e74\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLatest reported count\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Assets\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$120.21M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLatest financial reports\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Short-term Investments\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$12.77M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLatest financial reports\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e165,789 EUR\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFiscal Year 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue Growth (YoY)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e162.79%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024 vs 2023 (63,089 EUR)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe depth of scientific focus is evidenced by:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eProprietary technology targeting the \u003cstrong\u003eC5a\u003c\/strong\u003e and \u003cstrong\u003eC5aR\u003c\/strong\u003e signaling pathway of the complement cascade.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eThe lead drug, \u003cstrong\u003evilobelimab\u003c\/strong\u003e, was a result of early research by Co-founder\/CSO Prof. Renfeng Guo.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eThe CEO\/Founder, Prof. Riedemann, is named inventor on several internationally granted core patents of InflaRx.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eInflaRx N.V. (IFRX) - VRIO Analysis: 9. US Commercial Presence and Regulatory Experience\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Having a US subsidiary (InflaRx Pharmaceuticals Inc.) and generating revenue in the US (even if small) means they have established regulatory and initial commercial infrastructure.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; many European biotechs lack a fully established US footprint.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Temporary; building out a US presence takes time and capital, which they have already invested.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Good; they have the necessary legal and operational entities in place for future US product launches.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; this infrastructure is only valuable if a product gains US approval.\u003c\/p\u003e\n\u003cp\u003eThe US commercial and regulatory infrastructure is evidenced by the following financial and operational data:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003ePeriod\/Date\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS Subsidiary Location\u003c\/td\u003e\n\u003ctd\u003eAnn Arbor, Michigan\u003c\/td\u003e\n\u003ctd\u003eCurrent\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGOHIBIC Revenue (US Sales)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€0.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTwelve Months Ended December 31, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGOHIBIC Revenue (US Sales)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€124 thousand\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eThree Months Ended September 30, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS Sales and Marketing Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€4.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTwelve Months Ended December 31, 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS Personnel Costs (S\u0026amp;M)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€1.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTwelve Months Ended December 31, 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Group Employees\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e74\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDecember 31, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS IPO Gross Proceeds\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eUSD 106 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNovember 2017\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eKey US-relevant regulatory and operational milestones include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFDA Emergency Use Authorization (EUA) granted for GOHIBIC ($\\text{vilobelimab}$) in April 2023.\u003c\/li\u003e\n\u003cli\u003eUS Patent and Trademark Office granted a composition of matter patent for INF904 in 2022.\u003c\/li\u003e\n\u003cli\u003eCompletion of US Nasdaq IPO with gross proceeds of USD 106 million in November 2017.\u003c\/li\u003e\n\u003cli\u003eUS sales and marketing expenses incurred of €4.0 million for the twelve months ended December 31, 2023.\u003c\/li\u003e\n\u003cli\u003eRevenues from product sales in the United States for the twelve months ended December 31, 2024, totaled €0.2 million.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516185305237,"sku":"ifrx-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/ifrx-vrio-analysis.png?v=1740184382","url":"https:\/\/dcf-model.com\/products\/ifrx-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}